Caribou Biosciences, Inc. ( (CRBU) ) has released its Q3 earnings. Here is a breakdown of the information Caribou Biosciences, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in CRISPR genome-editing technologies to develop transformative therapies, particularly focusing on allogeneic CAR-T cell therapies for hematologic malignancies. In its latest earnings report, Caribou Biosciences revealed a net loss of $121.6 million for the nine months ending September 30, 2025, compared to a net loss of $113.6 million in the same period in 2024. The company’s revenue from licensing and collaboration slightly decreased to $7.2 million from $7.9 million year-over-year. Despite the financial losses, the company continues to invest heavily in research and development, with expenses totaling $85.6 million for the nine months ended September 30, 2025. Caribou Biosciences also reported a significant impairment charge of $12.2 million, primarily due to the full impairment of its investment in Edge Animal Health. Looking forward, Caribou Biosciences’ management remains focused on advancing its product candidates through clinical development and securing additional capital to support its operations, with existing cash and marketable securities expected to fund operations for at least the next 12 months.